Epilepsy Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | LifeSplice, Neuroene, Xenon Pharma, Epygenix, Addex Pharma, Cevevel,

Epilepsy Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | LifeSplice, Neuroene, Xenon Pharma, Epygenix, Addex Pharma, Cevevel,

“Delveinsight Business Research LLP”
As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 90+ pipeline drugs in the Epilepsy therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Epilepsy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Epilepsy Market. 

The Epilepsy Pipeline report embraces in-depth commercial, regulatory, and Epilepsy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Epilepsy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Epilepsy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Epilepsy treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Epilepsy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Epilepsy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Epilepsy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Epilepsy therapeutic market.

Epilepsy Therapeutics Landscape

There are approx. 75+ key companies are developing therapies for Epilepsy. Currently, SK Life Science is leading the therapeutics market with its Epilepsy drug candidates in the most advanced stage of clinical development.

Epilepsy Companies Actively Working in the Therapeutic Market Include:

  • UCB

  • SK Life Science

  • Stoke Therapeutics

  • Xenon Pharmaceuticals

  • Epygenix

  • Bright Minds Biosciences

  • Neurona Therapeutics

  • Cevevel Therapeutics

  • PTC Therapeutics

  • Addex Pharmaceuticals

  • Equilibre Biopharmaceuticals B.V.

  • ES Therapeutics Australia Pty Ltd

  • Overseas Pharmaceuticals

  • Anavex Life Sciences

  • Eliem Therapeutics

  • Ovid Therapeutics

  • CAMP4 Therapeutics

  • LifeSplice

  • Virpax Pharmaceuticals

  • Neuroene Therapeutics

And Many Others

Emerging and Marketed Epilepsy Drugs Covered in the Report Include:

  • ZX008 (Fenfluramine Hydrochloride): UCB

  • Cenobamate: SK Life Science, Inc.

  • STK-001: Stoke Therapeutics

  • EPX-100: Epygenix

  • NRTX-1001: Neurona Therapeutics 

  • BMB-101: Bright Minds Biosciences 

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Epilepsy Companies Working in the Market @

https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight

Analysis of Emerging Epilepsy Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

Learn How the Epilepsy Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Epilepsy Treatment Patterns

4. Epilepsy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Epilepsy Late Stage Products (Phase-III)

7. Epilepsy Mid-Stage Products (Phase-II)

8. Epilepsy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Epilepsy Discontinued Products

13. Epilepsy Product Profiles

14. Major Epilepsy Companies in the Market

15. Key Products in the Epilepsy Therapeutics Segment

16. Dormant and Discontinued Products

17. Epilepsy Unmet Needs

18. Epilepsy Future Perspectives

19. Epilepsy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Familial Hypercholesterolemia Market

“Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Familial Hypercholesterolemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Familial Hypercholesterolemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/